These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 18326690)
1. Targeting hypoxia, a novel treatment for advanced retinoblastoma. Boutrid H; Jockovich ME; Murray TG; Piña Y; Feuer WJ; Lampidis TJ; Cebulla CM Invest Ophthalmol Vis Sci; 2008 Jul; 49(7):2799-805. PubMed ID: 18326690 [TBL] [Abstract][Full Text] [Related]
2. Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma. Piña Y; Houston SK; Murray TG; Boutrid H; Celdran M; Feuer W; Shi W; Hernandez E; Lampidis TJ Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6149-56. PubMed ID: 20702830 [TBL] [Abstract][Full Text] [Related]
3. Increased hypoxia following vessel targeting in a murine model of retinoblastoma. Boutrid H; Piña Y; Cebulla CM; Feuer WJ; Lampidis TJ; Jockovich ME; Murray TG Invest Ophthalmol Vis Sci; 2009 Dec; 50(12):5537-43. PubMed ID: 19578014 [TBL] [Abstract][Full Text] [Related]
4. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice. Jockovich ME; Murray TG; Escalona-Benz E; Hernandez E; Feuer W Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1264-8. PubMed ID: 16565356 [TBL] [Abstract][Full Text] [Related]
5. Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors. Piña Y; Decatur C; Murray TG; Houston SK; Lopez-Cavalcante M; Hernandez E; Celdran M; Shah N; Feuer W; Lampidis T Invest Ophthalmol Vis Sci; 2012 Feb; 53(2):996-1002. PubMed ID: 22266512 [TBL] [Abstract][Full Text] [Related]
6. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Van Quill KR; Dioguardi PK; Tong CT; Gilbert JA; Aaberg TM; Grossniklaus HE; Edelhauser HF; O'Brien JM Ophthalmology; 2005 Jun; 112(6):1151-8. PubMed ID: 15885791 [TBL] [Abstract][Full Text] [Related]
8. Subconjunctival carboplatin in retinoblastoma: impact of tumor burden and dose schedule. Hayden BH; Murray TG; Scott IU; Cicciarelli N; Hernandez E; Feuer W; Fulton L; O'Brien JM Arch Ophthalmol; 2000 Nov; 118(11):1549-54. PubMed ID: 11074812 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of retinoblastoma tumor cell death after focal chemotherapy, radiation, and vascular targeting therapy in a mouse model. Jockovich ME; Suarez F; Alegret A; Piña Y; Hayden B; Cebulla C; Feuer W; Murray TG Invest Ophthalmol Vis Sci; 2007 Dec; 48(12):5371-6. PubMed ID: 18055783 [TBL] [Abstract][Full Text] [Related]
10. Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma. Murray TG; Cicciarelli N; O'Brien JM; Hernández E; Mueller RL; Smith BJ; Feuer W Arch Ophthalmol; 1997 Oct; 115(10):1286-90. PubMed ID: 9338675 [TBL] [Abstract][Full Text] [Related]
11. Paclitaxel in the treatment of retinal tumors of LH beta-Tag murine transgenic model of retinoblastoma. Suárez F; Jockovich ME; Hernandez E; Feuer W; Parel JM; Murray TG Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3437-40. PubMed ID: 17652710 [TBL] [Abstract][Full Text] [Related]
12. Iontophoretic delivery of carboplatin in a murine model of retinoblastoma. Hayden B; Jockovich ME; Murray TG; Kralinger MT; Voigt M; Hernandez E; Feuer W; Parel JM Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):3717-21. PubMed ID: 16936078 [TBL] [Abstract][Full Text] [Related]
13. Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds. Smith SJ; Pulido JS; Salomão DR; Smith BD; Mohney B Br J Ophthalmol; 2012 Aug; 96(8):1073-7. PubMed ID: 22368261 [TBL] [Abstract][Full Text] [Related]
14. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Abramson DH; Frank CM; Dunkel IJ Ophthalmology; 1999 Oct; 106(10):1947-50. PubMed ID: 10519590 [TBL] [Abstract][Full Text] [Related]
15. Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Kang SJ; Durairaj C; Kompella UB; O'Brien JM; Grossniklaus HE Arch Ophthalmol; 2009 Aug; 127(8):1043-7. PubMed ID: 19667343 [TBL] [Abstract][Full Text] [Related]
16. Hypoxia inhibits growth, proliferation, and increases response to chemotherapy in retinoblastoma cells. Yang Q; Tripathy A; Yu W; Eberhart CG; Asnaghi L Exp Eye Res; 2017 Sep; 162():48-61. PubMed ID: 28689747 [TBL] [Abstract][Full Text] [Related]
17. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Laurie NA; Gray JK; Zhang J; Leggas M; Relling M; Egorin M; Stewart C; Dyer MA Clin Cancer Res; 2005 Oct; 11(20):7569-78. PubMed ID: 16243833 [TBL] [Abstract][Full Text] [Related]
18. Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors. Houston SK; Piña Y; Murray TG; Boutrid H; Cebulla C; Schefler AC; Shi W; Celdran M; Feuer W; Merchan J; Lampidis TJ Clin Ophthalmol; 2011 Jan; 5():129-37. PubMed ID: 21339806 [TBL] [Abstract][Full Text] [Related]
19. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma. Tsui JY; Dalgard C; Van Quill KR; Lee L; Grossniklaus HE; Edelhauser HF; O'Brien JM Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):490-6. PubMed ID: 18234990 [TBL] [Abstract][Full Text] [Related]
20. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction. Demirci H; Eagle RC; Shields CL; Shields JA Arch Ophthalmol; 2003 Aug; 121(8):1125-31. PubMed ID: 12912690 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]